GlassScriptPhysician profile
Brian O'Donnell
NPI 1770106593
$1,547.45
in general payments reported to CMS, 2019-2025
12 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $66.10 · 2021: $120 · 2022: $29.87 · 2023: $387 · 2024: $834 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $229.61 | 2020-2024 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $213.38 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $205.30 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $162.30 | 2023-2025 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $100.01 | 2021 | |
| Shield Therapeutics INC | $75.88 | 2024 | |
| Sumitomo Pharma America, INC. | $55.74 | 2024 | Gemtesa |
| Abbott Laboratories | $20.47 | 2021 | |
| Theracosbio, LLC | $19.92 | 2023 | Brenzavvy |
| Abbvie INC. | $18.69 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.62 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian O'Donnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.